Asset
REZATAPOPT
PMV PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06054464 | phase1 | completed | 2023-09-19 | 2023-11-03 | PMV Pharmaceuticals, Inc | A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants |
| NCT06362642 | phase1 | completed | 2024-03-28 | 2024-10-22 | PMV Pharmaceuticals, Inc | A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants |
| NCT07372625 | phase1 | recruiting | 2026-02-04 | 2027-03-01 | PMV Pharmaceuticals, Inc | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. |
| NCT05249348 | phase1 | completed | 2021-12-20 | 2022-06-09 | PMV Pharmaceuticals, Inc | Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers |
| NCT04585750 | phase1_2 | recruiting | 2020-10-29 | 2026-12-15 | PMV Pharmaceuticals, Inc | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) |
FDA applications (0)
This company has no applications containing this asset.